Vitamin D3 Dose Requirement That Raises 25-Hydroxyvitamin D to Desirable Level in Overweight and Obese Elderly.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
18 08 2021
Historique:
received: 14 01 2021
pubmed: 7 5 2021
medline: 6 11 2021
entrez: 6 5 2021
Statut: ppublish

Résumé

Guidelines for the dosage of vitamin D supplementation vary widely globally. To investigate the impact of 2 vitamin D doses, bracketed between the IOM recommended dietary allowance (RDA) and the upper tolerable limit, on vitamin D nutritional status in elderly individuals. This post hoc analysis of data collected from a 12-month, double-blind, randomized control trial included 221 ambulatory participants (≥ 65 years) with a mean BMI of 30.2 kg/m2 and a mean baseline serum 25-hydroxyvitamin D [25(OH)D] level of 20.4 ± 7.4 ng/mL, who were recruited from 3 outpatient centers in Lebanon. All participants received 1000 mg of elemental calcium daily from calcium citrate plus the daily equivalent of either 600 IU or 3750 IU of vitamin D3. Mean 25(OH)D level at 12 months was 26.0 ng/mL with low dose and 36.0 ng/mL with high dose vitamin D3. The proportion of participants reaching a value ≥ 20 ng/mL was 86% in the low dose, and 99% in the high dose arms, with no gender differences. The increment of 25(OH)D per 100 IU/day was 1 ng/mL with the low dose, and 0.41 ng/mL with the high dose. Serum 25(OH)D levels at 1 year were highly variable in both treatment arms. Baseline 25(OH)D level and vitamin D dose-but not age, BMI, gender, or season-were significant predictors of serum 25(OH)D level post-intervention. The IOM Recommended Dietary Allowance (RDA) of 600 IU/day does not bring 97.5% of ambulatory elderly individuals above the desirable threshold of 20 ng/mL. Country-specific RDAs are best derived taking into account the observed variability and predictors of achieved 25(OH)D levels.

Identifiants

pubmed: 33954783
pii: 6268576
doi: 10.1210/clinem/dgab296
pmc: PMC8372651
doi:

Substances chimiques

Vitamins 0
Vitamin D 1406-16-2
Cholecalciferol 1C6V77QF41
25-hydroxyvitamin D A288AR3C9H
Calcium Citrate MLM29U2X85

Banques de données

ClinicalTrials.gov
['NCT01315366']

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e3644-e3654

Subventions

Organisme : FIC NIH HHS
ID : D43 TW009118
Pays : United States
Organisme : NIH HHS
ID : D43 TW009118
Pays : United States

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.

Auteurs

Dania S Bacha (DS)

Department of Internal Medicine, Division of Endocrinology, Calcium Metabolism and Osteoporosis Program, Beirut, Lebanon.

Maya Rahme (M)

Department of Internal Medicine, Division of Endocrinology, Calcium Metabolism and Osteoporosis Program, Beirut, Lebanon.

Laila Al-Shaar (L)

Scholars in Health Research Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.

Rafic Baddoura (R)

Department of Rheumatology, Hotel Dieu de France, Beirut, Lebanon.

Georges Halaby (G)

Department of Endocrinology, Hotel Dieu de France, Beirut, Lebanon.

Ravinder J Singh (RJ)

Division of Clinical Biochemistry and Immunology, Mayo Clinic, Rochester, MN, USA.

Ziyad R Mahfoud (ZR)

Department of Population Health Sciences, Weill Cornell Medicine, NY, USA.
Weill Cornell Medicine, Doha, Qatar.

Robert Habib (R)

STS Research Center, The Society of Thoracic Surgeons, Chicago, IL, USA.

Asma Arabi (A)

Department of Internal Medicine, Division of Endocrinology, Calcium Metabolism and Osteoporosis Program, Beirut, Lebanon.

Ghada El-Hajj Fuleihan (G)

Department of Internal Medicine, Division of Endocrinology, Calcium Metabolism and Osteoporosis Program, Beirut, Lebanon.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH